Dinov Borislav, Arya Arash, Bertagnolli Livio, Schirripa Valentina, Schoene Katharina, Sommer Philipp, Bollmann Andreas, Rolf Sascha, Hindricks Gerhard
From the Department of Cardiac Electrophysiology, Heart Center, University of Leipzig, Leipzig, Germany.
Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1144-51. doi: 10.1161/CIRCEP.114.001953. Epub 2014 Sep 27.
The effects of time to referral for catheter ablation (CA) of scar-related ventricular tachycardia (VT) on acute success, VT recurrence, and cardiac mortality are unclear.
We investigated 300 patients after CA of sustained VT. CA was performed within 30 days after the first documented VT in 75 (25%) patients (group 1), between 1 month and 1 year in 84 (28%) patients (group 2), and >1 year after the first VT occurrence in 141 (47%) patients (group 3). The end points were noninducibility of any VT after CA (acute success), VT recurrence and cardiac mortality after 2 years. Acute success was achieved in 66 (88%) patients in group 1, 68 (81%) in group 2, and in 99 (70.2%) in group 3 (P=0.008). During the 2-year follow-up period, VT recurred in 28 (37.3%) patients in group 1, 52 (61.9%) patients in group 2, and 91 (64.5%) patients in group 3 (P<0.0001). Recurrence-free survival was higher in group 1, as compared with group 2 (hazard ratio [HR], 1.85; P=0.009) and group 3 (HR, 2.04; P=0.001). No survival difference was observed between groups 1 and 2 (HR, 0.85; P=0.68) and groups 1 and 3 (HR, 1.13; P=0.73). β-blocker therapy, VT of ischemic origin, and complete success were associated with VT-free survival. VT recurrence (HR, 1.91; P=0.037) predicted cardiac mortality.
CA of scar-related VT performed within 30 days after the first documented VT was associated with improved acute and long-term success. VT recurrence, but not the early referral for CA, was associated with cardiovascular mortality.
瘢痕相关性室性心动过速(VT)导管消融(CA)的转诊时间对急性成功率、VT复发及心脏死亡率的影响尚不清楚。
我们对300例持续性VT行CA术后患者进行了研究。75例(25%)患者在首次记录VT后30天内行CA(1组),84例(28%)患者在1个月至1年内行CA(2组),141例(47%)患者在首次VT发作>1年后行CA(3组)。终点为CA术后任何VT不能被诱发(急性成功)、2年后VT复发及心脏死亡率。1组66例(88%)患者、2组68例(81%)患者、3组99例(70.2%)患者获得急性成功(P=0.008)。在2年随访期内,1组28例(37.3%)患者、2组52例(61.9%)患者、3组91例(64.5%)患者VT复发(P<0.0001)。与2组(风险比[HR],1.85;P=0.009)和3组(HR,2.04;P=0.001)相比,1组无复发生存率更高。1组与2组(HR,0.85;P=0.68)以及1组与3组(HR,1.13;P=0.73)之间未观察到生存差异。β受体阻滞剂治疗、缺血性起源的VT及完全成功与无VT生存相关。VT复发(HR,1.91;P=0.037)可预测心脏死亡率。
首次记录VT后30天内行瘢痕相关性VT的CA与急性及长期成功率提高相关。VT复发而非CA的早期转诊与心血管死亡率相关。